Abstract
The application of modern bioinformatics, 'omics' and molecular biology to research of fibrotic liver diseases holds promise to accelerate the development of new therapeutic targets and therapies for hepatic fibrosis. Specifically, progress is anticipated in delineating pathways of fibrosis reversal and functional compensation, and defining key determinants and presenting factors associated with fibrosis progression and reversion. These efforts will also lead to develop accurate biomarkers and methods for early noninvasive diagnosis, and to accelerate the testing of anti-fibrotic drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
